Agios Pharmaceuticals (NASDAQ:AGIO) Lifted to Sell at BidaskClub

Share on StockTwits

BidaskClub upgraded shares of Agios Pharmaceuticals (NASDAQ:AGIO) from a strong sell rating to a sell rating in a research note released on Thursday, BidAskClub reports.

AGIO has been the subject of a number of other reports. Cowen reaffirmed a buy rating on shares of Agios Pharmaceuticals in a report on Friday, May 31st. BMO Capital Markets assumed coverage on Agios Pharmaceuticals in a report on Thursday. They set an outperform rating and a $45.00 price target for the company. Royal Bank of Canada set a $89.00 price target on Agios Pharmaceuticals and gave the stock a buy rating in a report on Friday, August 2nd. Goldman Sachs Group reaffirmed a neutral rating and set a $55.00 price target on shares of Agios Pharmaceuticals in a report on Thursday, May 23rd. Finally, Zacks Investment Research upgraded Agios Pharmaceuticals from a sell rating to a hold rating and set a $46.00 target price on the stock in a research report on Wednesday, August 14th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and six have assigned a buy rating to the company’s stock. The company currently has an average rating of Hold and a consensus target price of $68.57.

Shares of NASDAQ AGIO opened at $37.74 on Thursday. The company has a market capitalization of $2.24 billion, a price-to-earnings ratio of -6.26 and a beta of 2.22. The company has a debt-to-equity ratio of 0.21, a current ratio of 5.96 and a quick ratio of 5.91. The business has a 50-day moving average of $40.70 and a two-hundred day moving average of $51.34. Agios Pharmaceuticals has a 1 year low of $33.17 and a 1 year high of $79.17.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.87) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.70) by ($0.17). The business had revenue of $26.22 million for the quarter, compared to analysts’ expectations of $27.05 million. Agios Pharmaceuticals had a negative return on equity of 59.89% and a negative net margin of 383.05%. The firm’s quarterly revenue was down 35.1% on a year-over-year basis. During the same period last year, the firm earned ($1.19) earnings per share. As a group, equities research analysts expect that Agios Pharmaceuticals will post -7.12 earnings per share for the current year.

Institutional investors and hedge funds have recently bought and sold shares of the company. TD Asset Management Inc. increased its position in shares of Agios Pharmaceuticals by 26.6% during the first quarter. TD Asset Management Inc. now owns 52,668 shares of the biopharmaceutical company’s stock worth $3,552,000 after purchasing an additional 11,068 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of Agios Pharmaceuticals by 27.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 182,150 shares of the biopharmaceutical company’s stock worth $8,399,000 after purchasing an additional 39,255 shares in the last quarter. Baillie Gifford & Co. increased its position in shares of Agios Pharmaceuticals by 23.8% during the second quarter. Baillie Gifford & Co. now owns 1,079,829 shares of the biopharmaceutical company’s stock worth $53,862,000 after purchasing an additional 207,604 shares in the last quarter. Aperio Group LLC increased its position in shares of Agios Pharmaceuticals by 123.7% during the second quarter. Aperio Group LLC now owns 17,551 shares of the biopharmaceutical company’s stock worth $875,000 after purchasing an additional 9,705 shares in the last quarter. Finally, Comerica Bank increased its position in shares of Agios Pharmaceuticals by 37.7% during the second quarter. Comerica Bank now owns 18,738 shares of the biopharmaceutical company’s stock worth $909,000 after purchasing an additional 5,130 shares in the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.

Read More: Market Indexes

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Gluskin Sheff + Associates  Earns Daily News Impact Score of -3.33
Gluskin Sheff + Associates Earns Daily News Impact Score of -3.33
Kering  PT Set at €602.00 by Goldman Sachs Group
Kering PT Set at €602.00 by Goldman Sachs Group
Camden Property Trust  Receives Buy Rating from Barclays
Camden Property Trust Receives Buy Rating from Barclays
Global Payments  Now Covered by UBS Group
Global Payments Now Covered by UBS Group
Essential Properties Realty Trust  Rating Reiterated by Barclays
Essential Properties Realty Trust Rating Reiterated by Barclays
Delta Apparel, Inc.  Sees Significant Decrease in Short Interest
Delta Apparel, Inc. Sees Significant Decrease in Short Interest


© 2006-2019 Ticker Report